Wordt geladen...
The current treatment landscape in the UK for stage III NSCLC
For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease. Although curable, stage III NSCLC encompasses a diverse range of disease presentation, with an equally complex range...
Bewaard in:
| Gepubliceerd in: | Br J Cancer |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group UK
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7735211/ https://ncbi.nlm.nih.gov/pubmed/33293670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01069-z |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|